MX9302917A - Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene. - Google Patents

Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.

Info

Publication number
MX9302917A
MX9302917A MX9302917A MX9302917A MX9302917A MX 9302917 A MX9302917 A MX 9302917A MX 9302917 A MX9302917 A MX 9302917A MX 9302917 A MX9302917 A MX 9302917A MX 9302917 A MX9302917 A MX 9302917A
Authority
MX
Mexico
Prior art keywords
derivatives
famaceutical
procedure
preparation
formulation containing
Prior art date
Application number
MX9302917A
Other languages
English (en)
Inventor
Bruce Edward Gerlitz Grinnell
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9302917A publication Critical patent/MX9302917A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Veterinary Medicine (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Se describen derivados de proteína C humana con alta actividad y dependencia reducida sobre la activación de la trombina. Estos derivados difieren de las formas nativas o naturales de la proteína C humana en sus velocidades incrementadas de activación, sus actividades funcionales y sus estructuras de carbohidratos. También se describen los compuestos de DNA, los vectores de transferencia, los vectores de expresión y los transformadores útiles para la producción de estos derivados.
MX9302917A 1992-05-21 1993-05-19 Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene. MX9302917A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US88719192A 1992-05-21 1992-05-21

Publications (1)

Publication Number Publication Date
MX9302917A true MX9302917A (es) 1993-11-01

Family

ID=25390640

Family Applications (1)

Application Number Title Priority Date Filing Date
MX9302917A MX9302917A (es) 1992-05-21 1993-05-19 Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.

Country Status (23)

Country Link
US (1) US5453373A (es)
EP (1) EP0575054B1 (es)
JP (1) JP3564150B2 (es)
KR (1) KR100291529B1 (es)
CN (1) CN1080658A (es)
AT (1) ATE286121T1 (es)
AU (1) AU661901B2 (es)
BR (1) BR9301944A (es)
CA (1) CA2096604C (es)
CZ (1) CZ286016B6 (es)
DE (1) DE69333727T2 (es)
DK (1) DK0575054T3 (es)
ES (1) ES2233925T3 (es)
FI (1) FI932282A (es)
HU (1) HU218408B (es)
IL (1) IL105757A0 (es)
MX (1) MX9302917A (es)
MY (1) MY110664A (es)
NO (1) NO311299B1 (es)
NZ (1) NZ247651A (es)
PH (1) PH29911A (es)
PT (1) PT575054E (es)
RU (1) RU2122004C1 (es)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2067525C (en) * 1991-05-09 1998-09-15 Helmut G. Alt Organometallic fluorenyl compounds, preparation and use
AT402262B (de) * 1991-06-20 1997-03-25 Immuno Ag Arzneimittel enthaltend aktiviertes protein c
AU2870992A (en) * 1991-10-04 1993-05-03 Board Of Regents Of The University Of Nebraska, The A soluble thrombomodulin-based one-stage assay for vitamin k-dependent coagulation-inhibiting proteins
US5716795A (en) * 1991-10-04 1998-02-10 Matschiner; John T. Thrombomodulin-based coagulometric assay of the protein C system
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US6159468A (en) 1997-04-28 2000-12-12 Eli Lilly And Company Activated protein C formulations
US6630137B1 (en) 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
KR20010013413A (ko) * 1997-06-05 2001-02-26 피터 지. 스트링거 혈전성 질환의 치료 방법
HUP0001237A3 (en) 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
AU5131699A (en) * 1998-07-31 2000-02-21 Eli Lilly And Company Cryogranulation of activated protein c
WO2000023101A1 (en) 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
CA2351067A1 (en) 1998-11-13 2000-05-25 Eli Lilly And Company Method of treating heparin-induced thrombocytopenia
CN1326356A (zh) 1998-11-20 2001-12-12 伊莱利利公司 治疗病毒性出血热的方法
AU1723200A (en) 1998-11-23 2000-06-13 Eli Lilly And Company Method of treating sickle cell disease and thalassemia
US6998122B1 (en) * 1999-04-30 2006-02-14 Eli Lilly And Company Protein C derivatives
AU1751801A (en) * 1999-11-19 2001-05-30 Eli Lilly And Company Protein c derivatives
DE60108076T2 (de) * 2000-02-02 2006-03-16 Eli Lilly And Co., Indianapolis Protein c derivate
US6630138B2 (en) 2000-02-11 2003-10-07 Eli Lilly And Company Protein C derivatives
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
AU2002210388B2 (en) * 2000-10-18 2006-11-23 Perseid Therapeutics Llc Protein C or activated protein C like molecules
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
CN100392079C (zh) * 2000-10-18 2008-06-04 马克西根公司 蛋白c或活化的蛋白c-样分子
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
AU2003213146A1 (en) * 2002-03-08 2003-09-22 Eli Lilly And Company Activated protein c formulations
AU2003232176A1 (en) * 2002-06-14 2003-12-31 Maxygen Aps Protein c variants with altered properties
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
WO2006014839A2 (en) * 2004-07-23 2006-02-09 The University Of Rochester Activated protein c inhibits undesirable effects of plasminogen activator in the brain
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
WO2007140625A1 (en) * 2006-06-09 2007-12-13 The University Of British Columbia Interferon gamma polymorphisms as indicators of subject outcome in critically ill subjects
ATE520414T1 (de) * 2007-06-18 2011-09-15 Univ Oregon Health & Science Protein c zur verwendung bei der aufrechterhaltung der hämostase
WO2009089620A1 (en) * 2008-01-15 2009-07-23 The Universityof British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
CN104262479A (zh) 2008-12-19 2015-01-07 国家健康与医学研究院 丝氨酸蛋白酶衍生物及其在凝血功能障碍的预防或治疗中的用途
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
US20150150954A1 (en) 2012-07-04 2015-06-04 The University Of Sydney Treatment of inflammatory skin disorders
WO2015157791A1 (en) 2014-04-16 2015-10-22 The University Of Sydney Treatment of abnormal cutaneous scarring
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US4981952A (en) * 1988-10-04 1991-01-01 Eli Lilly And Company Method for the purification of vitamin K-dependent proteins
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c

Also Published As

Publication number Publication date
DK0575054T3 (da) 2005-04-25
NO311299B1 (no) 2001-11-12
FI932282A0 (fi) 1993-05-19
NO931840L (no) 1993-11-22
RU2122004C1 (ru) 1998-11-20
FI932282A (fi) 1993-11-22
NZ247651A (en) 1995-03-28
KR930023370A (ko) 1993-12-18
PT575054E (pt) 2005-03-31
JP3564150B2 (ja) 2004-09-08
CN1080658A (zh) 1994-01-12
HU218408B (hu) 2000-08-28
US5453373A (en) 1995-09-26
DE69333727D1 (de) 2005-02-03
NO931840D0 (no) 1993-05-19
CA2096604A1 (en) 1993-11-22
BR9301944A (pt) 1993-11-30
PH29911A (en) 1996-09-16
EP0575054B1 (en) 2004-12-29
KR100291529B1 (ko) 2001-06-01
EP0575054A2 (en) 1993-12-22
IL105757A0 (en) 1993-09-22
MY110664A (en) 1999-01-30
ES2233925T3 (es) 2005-06-16
AU3869993A (en) 1993-11-25
ATE286121T1 (de) 2005-01-15
CZ94893A3 (en) 1994-01-19
CZ286016B6 (cs) 1999-12-15
DE69333727T2 (de) 2005-12-15
HU9301461D0 (en) 1993-09-28
HUT69615A (en) 1995-09-28
JPH0680698A (ja) 1994-03-22
AU661901B2 (en) 1995-08-10
CA2096604C (en) 2003-12-16
EP0575054A3 (en) 1995-04-19

Similar Documents

Publication Publication Date Title
MX9302917A (es) Derivados de proteinas c humanas, procedimiento para su preparacion y formulacion famaceutica que los contiene.
ATE162221T1 (de) Herstellung von glukoseoxidase in rekombinanten systemen
MY102472A (en) Preparation of funtional human urokinase proteins.
ATE64529T1 (de) Hexadecylphosphocolin enthaltende arzneimittel mit antitumorwirkung.
ES2035384T3 (es) Procedimiento para la esterilizacion de sangre, plasma, derivados de la sangre y del plasma, suspensiones celulares o similares.
NO179436C (no) Fremgangsmåte for fremstilling av farmasöytiske produkter for topisk bruk
PT86771A (pt) Process for preparing 4-substituted benzamide derivatives with anticonvulsant activity
NO902104D0 (no) Kosmetisk blanding.
DK90188A (da) Kombinationsprodukter indeholdende picolin- eller 2-pyridyloxyeddikesyre-derivater, praeparater omfattende saadanne produkter og anvendelse deraf som herbicider
NO891926L (no) Fremgangsmaate for fremstilling av stabile protein- eller peptidpreparater.
ES2051953T3 (es) Derivados isomeros de trimetilbiciclo(4,3,0)nonano.
ATE80143T1 (de) Isomere formyl-trimethylbicyclo(2,2,2)oct-7-ene.
NO902405D0 (no) Vevplasminogenaktivatorderivat, dna-sekvens og ekspresjonsplasmid, samt fremgangsmaate for fremstilling av plasmidet.
DK381989D0 (da) Maerkede benzodiazepiner
DE3579140D1 (de) Arzneimittel mit einem 6-substituierten adenosin als aktives bestandteil.
DE3773322D1 (de) Pharmazeutische zubereitungen mit heilender aktivitaet.
ATE104966T1 (de) 9-(acylamino)tetrahydroacridinderivate und wahrnehmungssteigernde mittel davon als aktiver wirkstoff.
NO905375D0 (no) Fremg. og preparater for behandling av pattedyr-infeksjoner under anv. av medikamenter som omfatter hymenoptera venom, protein- eller polypepti-komponenter derav, eller analoger av slike protein- eller polypeptid-komponenter.
ES1004605Y (es) Nuevo dispositivo de union de las ramas de peinetas y pasadores articulados para el cabello.